TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03824938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 650mg Oral Capsule
Description: A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
Study: NCT01703221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Placebo to sitagliptin 50 mg tablet administered orally once daily
Study: NCT00954135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozolo+cyclophosphamide
Description: Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozolo+sorafenib+cyclophosphamide
Description: Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months
Study: NCT00829283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One pill daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine/Orlistat
Description: Sibutramine 15 mg daily or Orlistat 120mg TID
Study: NCT01444391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tube placement (Acclarent iontophoresis device)
Description: Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
Study: NCT02587247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF2 antibody/68Ga-IMP-288
Description: TF2 antibody coupled with 68Ga-IMP-288
Study: NCT01652911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sernova Cell Pouch
Description: The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
Study: NCT03824938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Tablet 650mg
Description: A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
Study: NCT02576834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention
Description: 10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
Study: NCT01934543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
Study: NCT02586883

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bronchial ddp test
Description: bronchial ddp test during endoscopy, nasal smear, bronchial smear

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bronchial ddp test
Description: bronchial ddp test during endoscopy, nasal smear, bronchial smear

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bronchial ddp test
Description: bronchial ddp test during endoscopy, nasal smear, bronchial smear
Study: NCT02821676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction
Description: 30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
Study: NCT00536861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity
Study: NCT03211806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior
Description: Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bluetooth-enabled activity monitor
Description: Monitoring activity using a Bluetooth-enabled activity monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bluetooth-enabled activity monitor
Description: Monitoring activity using a Bluetooth-enabled activity monitor
Study: NCT01039012

Intervention type: OTHER
Group type: OTHER
Intervention: Tai Chi
Description: Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Participant follow the standard care recommended by their physician.
Study: NCT02273739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
Study: NCT03206905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty
Description: endoscopic, rather than surgical approach, to perform sleeve gastroplasty

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: nutritional/exercise counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: nutritional/exercise counseling
Study: NCT03641079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinjal peel extract containing cream
Description: Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
Study: NCT03589430

Intervention type: OTHER
Intervention: Laboratory investigations ( protein C, protein S , antithrombin III)
Description: laboratory investigations ( protein C , protein S , antithrombin)

Intervention type: OTHER
Intervention: Laboratory investigations ( protein C, protein S , antithrombin III)
Description: laboratory investigations ( protein C , protein S , antithrombin)

Intervention type: OTHER
Intervention: Laboratory investigations ( protein C, protein S , antithrombin III)
Description: laboratory investigations ( protein C , protein S , antithrombin)
Study: NCT01786018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant (HCT)
Description: Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10\^7 CD3 cells/kg recipient weight and cryopreserved.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cytoreduction
Description: Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression
Description: Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: (FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection and infusions of Donor PBSC
Description: Collection and infusions of Donor PBSC
Study: NCT02624700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm A: Pemetrexed
Description: Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm A: Sorafenib
Description: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm B: Pemetrexed
Description: Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm B: Sorafenib
Description: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
Study: NCT01707875

Intervention type: OTHER
Intervention: fetal brain neurosonography
Description: fetal brain neurosonography according to the ISUG guidelines
Study: NCT04685603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
Study: NCT03644797

Intervention type: GENETIC
Intervention: Exome sequencing
Description: Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
Study: NCT03863496

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scoliosis surgery
Description: All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
Study: NCT01771094

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Effect of sweetness of the beverage in thirst sensation
Description: Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of sweetness of the beverage in thirst sensation
Description: Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of sweetness of the beverage in thirst sensation
Description: Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
Study: NCT00649298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haemodialysis
Description: Comparison of different weekly duration of haemodialysis treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: haemodialysis
Description: Comparison of different weekly duration of haemodialysis treatment
Study: NCT03364998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Damoctocog (Jivi, BAY94-9027)
Description: 60 international units (IU)/kg, given as a 10 minute injection, 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Damoctocog (Jivi, BAY94-9027)
Description: 60 international units (IU)/kg, given as a 10 minute injection, 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elocta
Description: 60 IU/kg, given as a 10 minute injection, 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elocta
Description: 60 IU/kg, given as a 10 minute injection, 1 dose
Study: NCT03312010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator HF
Description: A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal Cord Stimulator Sham
Description: A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
Study: NCT02522481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
Study: NCT02046135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Study: NCT00136604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib-MenAC
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
Study: NCT02094846

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice messages
Description: Voice messages reinforced with self-efficacy
Study: NCT01717846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 or Orencia treated group
Description: Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Group 2 (DMARDS treated group)
Description: Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
Study: NCT01691729

Intervention type: DEVICE
Group type: OTHER
Intervention: Ostomy accessory
Description: Wearing each of the devices for 10 days each

Intervention type: DEVICE
Group type: OTHER
Intervention: Ostomy accessory
Description: Wearing each of the devices for 10 days each

Intervention type: DEVICE
Group type: OTHER
Intervention: Ostomy accessory
Description: Wearing each of the devices for 10 days each

Intervention type: DEVICE
Group type: OTHER
Intervention: Ostomy accessory
Description: Wearing each of the devices for 10 days each

Intervention type: DEVICE
Group type: OTHER
Intervention: Ostomy accessory
Description: Wearing each of the devices for 10 days each

Intervention type: DEVICE
Group type: OTHER
Intervention: Ostomy accessory
Description: Wearing each of the devices for 10 days each
Study: NCT01381523

Intervention type: DRUG
Intervention: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)
Description: Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data

Intervention type: DRUG
Intervention: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)
Description: Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data

Intervention type: DRUG
Intervention: Single-entity oral triptans
Description: Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.

Intervention type: DRUG
Intervention: Single-entity oral triptans
Description: Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
Study: NCT01666522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
Study: NCT04453956

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with the assistance of EndoAngel's polyp detection function.
Description: Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with the assistance of EndoAngel's polyp detection function.
Description: Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with the assistance of EndoAngel's quality monitoring function.
Description: Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with the assistance of EndoAngel's quality monitoring function.
Description: Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Colonoscopy without the assistance of EndoAngel's any function.
Description: Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
Study: NCT02143271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration